Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Acute Right Ventricular Failure in a Patient with Hepatic Cirrhosis
Soto, Jose Soto , Geiger, Xochiquetzal J., Johnson, Margaret M.

Case Reports in Pulmonology | December 18, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-3

10.1155/2012/127583 | PMID 23316403 Get It

Pulmonary embolic disease is most commonly a manifestation of venous thromboembolism (VTE). However, fat, tumor, and air may all embolize to the pulmonary vasculature and lymphatics resulting in various clinical manifestations. Tumor emboli to small pulmonary vessels and lymphatics can lead to hypoxemic respiratory failure and shock. We present a 62-year-old male with history of mild COPD and end-stage liver disease secondary to hepatitis C admitted due to progressive shortness of breath and hypoxemia who developed shock and right ventricular failure. After a negative evaluation for venous thromboembolic disease, he had progressive respiratory and hemodynamic deterioration despite mechanical ventilation, renal replacement therapy, and vasopressive/inotropic support. Postmortem examination revealed diffuse micronodular moderately differentiated hepatocellular carcinoma (HCC) without a discrete mass, as well as numerous HCC tumor emboli to the lung and focally to the heart, consistent with disseminated hepatocellular tumor microembolism.
Traffic Jam at the Blood–Brain Barrier Promotes Greater Accumulation of Alzheimer’s Disease Amyloid-β Proteins in the Cerebral Vasculature
Agyare, Edward K., Leonard, Sarah R., Curran, Geoffry L., Yu, Caroline C., Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Paravastu, Anant K. , Kandimalla, Karunya K

Molecular Pharmaceutics | December 18, 2012 | Volume: 10 | Issue: 5 | Pages: 1557-1565

10.1021/mp300352c | PMID 23249146 Get It

How does doxorubicin work?
Patel, Anand G. , Kaufmann, Scott H. , Kaufmann, Scott H

eLife | December 18, 2012 | Volume: 1 | Issue: No issue available | Pages: No page available

10.7554/elife.00387 | PMID 23256047 Get It

A new mechanism involving cleavage of a transcription factor called CREB3L1 has been proposed to explain the anti-tumour effects of doxorubicin.
PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
Hockla, Alexandra , Miller, Erin , Salameh, Moh’d A., Copland, John A. , Radisky, Evette S. , Radisky, Derek C. , Radisky, Evette S

Molecular Cancer Research | December 18, 2012 | Volume: 10 | Issue: 12 | Pages: 1555-1566

10.1158/1541-7786.mcr-12-0314 | PMID 23258495 Get It

Abstract PRSS3/mesotrypsin is an atypical isoform of trypsin that has been associated with breast, lung, and pancreatic cancer cell malignancy. In analyses of open source transcriptional microarray data, we find that PRSS3 expression is upregulated in metastatic prostate cancer tissue, and that expression of PRSS3 in primary prostate tumors is prognostic of systemic progression following prostatectomy. Using a mouse orthotopic model with bioluminescent imaging, we show that PRSS3/mesotrypsin is critical for prostate cancer metastasis. Silencing of PRSS3 inhibits anchorage-independent growth of prostate cancer cells in soft agar assays, and suppresses invasiveness in Matrigel transwell assays and three-dimensional (3D) cell culture models. We further show that treatment with recombinant mesotrypsin directly promotes an invasive cellular phenotype in prostate cancer cells and find that these effects are specific and require the proteolytic activity of mesotrypsin, because neither cationic trypsin nor a mesotrypsin mutant lacking activity can drive the invasive phenotype. Finally, we show that a newly developed, potent inhibitor of mesotrypsin activity can suppress prostate cancer cell invasion to a similar extent as PRSS3 gene silencing. This study defines mesotrypsin as an important mediator of prostate cancer progression and metastasis, and suggests that inhibition of mesotrypsin activity may provide a novel modality for prostate cancer treatment. Mol Cancer Res; 10(12); 1555–66. ©2012 AACR.
VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx
Ngok, Siu P., Geyer, Rory, Liu, Miaoliang, Kourtidis, Antonis , Agrawal, Sudesh, Wu, Chuanshen, Seerapu, Himabindu Reddy, Lewis‐Tuffin, Laura J. , Moodie, Karen L , Deborah, Huveldt, Marx, Ruth, Baraban, Jay M. , Störz, Peter , Horowitz, Arie , Anastasiadis, Panos Z.

Journal of Cell Biology | December 17, 2012 | Volume: 199 | Issue: 7 | Pages: 1103-1115

10.1083/jcb.201207009 | PMID 23253477 Get It

Vascular endothelial growth factor (VEGF) and Ang1 (Angiopoietin-1) have opposing effects on vascular permeability, but the molecular basis of these effects is not fully known. We report in this paper that VEGF and Ang1 regulate endothelial cell (EC) junctions by determining the localization of the RhoA-specific guanine nucleotide exchange factor Syx. Syx was recruited to junctions by members of the Crumbs polarity complex and promoted junction integrity by activating Diaphanous. VEGF caused translocation of Syx from cell junctions, promoting junction disassembly, whereas Ang1 maintained Syx at the junctions, inducing junction stabilization. The VEGF-induced translocation of Syx from EC junctions was caused by PKD1 (protein kinase D1)-mediated phosphorylation of Syx at Ser806, which reduced Syx association to its junctional anchors. In support of the pivotal role of Syx in regulating EC junctions, syx−/− mice had defective junctions, resulting in vascular leakiness, edema, and impaired heart function.
Tumor-Induced Osteomalacia Caused by Primary Fibroblast Growth Factor 23 Secreting Neoplasm in Axial Skeleton: A Case Report
Gandhi, Gunjan Y. , Shah, Aashish A., Wu, Kevin J. , Shoraka, Ali Reza, Gupta, Vivek

Case Reports in Endocrinology | December 17, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-5

10.1155/2012/185454 | PMID 23346426 Get It

We report the case of a 66-year-old woman with tumor-induced osteomalacia (TIO) caused by fibroblast growth factor 23 (FGF-23) secreting mesenchymal tumor localized in a lumbar vertebra and review other cases localized to the axial skeleton. She presented with nontraumatic low back pain and spontaneous bilateral femur fractures. Laboratory testing was remarkable for low serum phosphorus, phosphaturia, and significantly elevated serum FGF-23 level. Magnetic resonance imaging (MRI) of the lumbar spine showed a focal lesion in the L-4 vertebra which was hypermetabolic on positron emission tomography (PET) scan. A computed tomography (CT) guided needle biopsy showed a low grade spindle cell neoplasm with positive FGF-23 mRNA expression by reverse transcriptase polymerase chain reaction (RT-PCR), confirming the diagnosis of a phosphaturic mesenchymal tumor mixed connective tissue variant (PMTMCT). The patient elected to have surgery involving anterior resection of L-4 vertebra with subsequent normalization of serum phosphorus. Including the present case, we identified 12 cases of neoplasms localized to spine causing TIO. To our knowledge, this paper represents the first documented case of lumbar vertebra PMT causing TIO. TIO is a rare metabolic bone disorder that carries a favorable prognosis. When a lesion is identifiable, surgical intervention is typically curative.
Lymphangioleiomyomatosis: Calling It What It Is: A Low-Grade, Destructive, Metastasizing Neoplasm
McCormack, Francis X. , Colby, Thomas V. , Moss, Joel , Travis, William D. , Henske, Elizabeth P. , McCormack, Francis X

American Journal of Respiratory and Critical Care Medicine | December 17, 2012 | Volume: 186 | Issue: 12 | Pages: 1210-1212

10.1164/rccm.201205-0848oe | PMID 23250499 Get It

Improvement in Student Science Proficiency Through InSciEd Out
Pierret, Chris , Sonju, James D., Leicester, Jean E., Hoody, Maggie, LaBounty, Thomas J., Frimannsdottir, Katrin R., Ekker, Stephen C. , Ekker, Stephen C

Zebrafish | December 17, 2012 | Volume: 9 | Issue: 4 | Pages: 155-168

10.1089/zeb.2012.0818 | PMID 23244687 Get It

Abstract Integrated Science Education Outreach (InSciEd Out) is a collaboration formed between Mayo Clinic, Winona State University, and Rochester Public Schools (MN) with the shared vision of achieving excellence in science education. InSciEd Out employs an equitable partnership model between scientists, teachers, education researchers, and the community. Teams of teachers from all disciplines within a single school experience cutting-edge science using the zebrafish model system, as well as current pedagogical methods, during a summer internship at the Mayo Clinic. Within the internship, the teachers produce new curriculum that directly addresses opportunities for science education improvement at their own school. Zebrafish are introduced within the new curriculum to support a living model of the practice of science. Following partnership with the InSciEd Out program and 2 years of implementation in the classroom, teacher-interns from a K–8 public school reported access to local scientific technology and expertise they had not previously recognized. Teachers also reported improved integration of other disciplines into the scientific curriculum and a flow of concepts vertically from K through 8. Students more than doubled selection of an Honors science track in high school to nearly 90%. 98% of students who took the Minnesota Comprehensive Assessments in their 5 th and 8 th grade year (a span that includes 2 years of InSciEd Out) showed medium or high growth in science proficiency. These metrics indicate that cooperation between educators and scientists can result in positive change in student science proficiency and demonstrate that a higher expectation in science education can be achieved in US public schools.
Reducing the Noise in Behavioral Assays: Sex and Age in Adult Zebrafish Locomotion
Philpott, Catelyn, Donack, Corey J., Cousin, Margot A. , Pierret, Chris

Zebrafish | December 17, 2012 | Volume: 9 | Issue: 4 | Pages: 191-194

10.1089/zeb.2012.0764 | PMID 23244690 Get It

Abstract Many assays are used in animal model systems to measure specific human disease-related behaviors. The use of both adult and larval zebrafish as a behavioral model is gaining popularity. As this work progresses and potentially translates into new treatments, we must do our best to improve the sensitivity of these assays by reducing confounding factors. Scientists who use the mouse model system have demonstrated that sex and age can influence a number of behaviors. As a community, they have moved to report the age and sex of all animals used in their studies. Zebrafish work does not yet carry the same mandate. In this study, we evaluated sex and age differences in locomotion behavior. We found that age was a significant factor in locomotion, as was sex within a given age group. In short, as zebrafish age, they appear to show less base level locomotion. With regard to sex, younger (10 months) zebrafish showed more locomotion in males, while older zebrafish (22 months) showed more movement in females. These findings have led us to suggest that those using the zebrafish for behavioral studies control for age and sex within their experimental design and report these descriptors in their methods.